Abstract: The present invention concerns a new process for the preparation of voclosporin in amorphous form.

Abstract: The present invention relates to compositions comprising an American cranberry extract combined with phospholipids, and the use thereof in the prevention and treatment of urinary tract infections. The invention also relates to processes for the preparation of said compositions, and formulations for oral administration comprising said compositions.

Abstract: The present invention relates to solid dispersions comprising a salt of ursolic acid with an alkali metal and a phospholipid and to oral dosage formulations containing them. The invention also relates to processes for preparing the solid dispersions and to the use of the solid dispersions and formulations for the prevention and/or treatment of a variety of pathological conditions in which hepatoprotective, antioxidant, anti-inflammatory, antiviral and cytotoxic activities are desired.

Abstract: A process for the synthesis of Cannabidiol of formula (1): (1) is herein disclosed. The process comprises contacting a solution [solution (S1)] of (+)-p-mentha-diene-3-ol of formula (4) (4) or an ester thereof and olivetol of formula (3): (3) with a solution [solution (S2)] of a non-supported Lewis acid in a continuous flow reactor and treatment of the resulting mixture with a basic solution. The process offers the advantage that it can be conveniently carried out on an industrial scale while avoiding the formation of abnormal CBD and THC (?9-tetrahydrocannabinol).

Abstract: Disclosed is a method for the identification of Vaccinium myrtillus in a botanical composition and a kit specifically designed for its implementation. The method is based on the detection, using PCR amplification, of nucleic acid fragments within a genomic region of Vaccinium myrtillus.

Abstract: Disclosed is a process for the preparation of taxanes esterified with octadecanedioic acid which comprises reacting a taxane with an octadecanedioic acid protected in one of the two carboxyl groups and protected with a group removable by catalysis with transition metals.

Abstract: The invention relates to a process for the preparation of colchicine 1 from colchicoside 2 which comprises enzymatic conversion of colchicoside 2 to 3-O-demethylcolchicine 3, wherein the enzyme used is a cellulase. According to another aspect of the invention, 3-O-demethylcolchicine 3 can be converted to colchicine 1 using an alkylating agent. The invention also relates to a process for enriching the colchicine 1 content of extracts from plants belonging to the Colchicaceae family containing colchicine 1, colchicoside 2 and 3-O-demethylcolchicine 3, which comprises conversion by means of a colchicoside 2 cellulase to 3-O-demethylcolchicine 3, followed by conversion of 3-O-demethylcolchicine 3 to colchicine 1 using an alkylating agent.

Abstract: Disclosed are powder solid compositions including a hydroalcoholic extract of Bergamot fruit (Citrus aurantium var. bergamia) and at least one phospholipid. Also disclosed is a process for the preparation of the compositions. The compositions are useful for the prevention and/or treatment of dysmetabolic syndromes, dyslipidemias and type 2 diabetes.

Abstract: Disclosed is a process for the purification of staurosporine (1), which comprises salification of staurosporine (1) (Formula (1)) by treatment with a mineral acid to give a precipitated salt, isolation of the staurosporine (1) precipitated salt, treatment of the staurosporine (1) isolated salt with an organic base, and isolation of staurosporine (1). Also disclosed are novel polymorphic forms of the mono- and bis-hydrochloride salts of staurosporine (1).

Abstract: Compositions comprising a solid dispersion of quercetin are useful in the treatment and/or prevention of ocular affections.

Abstract: The present invention relates to compositions comprising an American cranberry extract combined with phospholipids, and the use thereof in the prevention and treatment of urinary tract infections. The invention also relates to processes for the preparation of said compositions, and formulations for oral administration comprising said compositions.

Abstract: The invention relates to an amorphous solid dispersion comprising ferric maltol and a polymer, and the preparation process thereof.

Abstract: The invention relates to a process for the preparation of Melphalan (4-[bis(2-chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: —N(CH2CH2OS(O)nO?)2, wherein n is 1 or 2 followed by conversion of the —N(CH2CH2OS(O)nO?)2 group into a —N(CH2CH2Cl)2 group. The invention also provides novel intermediates useful for the preparation of Melphalan.

Abstract: The present invention relates to a composition comprising cannabidiol and at least two excipients, wherein at least one excipient is a lipid excipient and wherein at least one excipient is a hydrophilic excipient, and wherein the lipid excipient is present in an amount equal to or lower than 20% of the total weight of the composition; the invention also relates to the preparation process of the composition and to pharmaceutical or nutraceutical formulations containing it.

Abstract: Disclosed are compositions including berberine combined with pea proteins and one or more surfactants. Also disclosed are processes for the preparation of the compositions, and the formulations and uses thereof.

Abstract: The invention relates to a process for the preparation of Melphalan (4-[bis(2-5 chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: —N(CH2CH2OS(O)nO—)2, wherein n is 1 or 2 followed by conversion of the ?N(CH2CH2OS(O)nO—)2 group into a —N(CH2CH2Cl)2 group. The invention also provides novel intermediates useful for the preparation of Melphalan.

Abstract: The invention relates to a process for the preparation of Melphalan (4-[bis(2-chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: —N(CH2CH2OS(O)nO?)2, wherein n is 1 or 2 followed by conversion of the —N(CH2CH2OS(O)nO?)2 group into a —N(CH2CH2Cl)2 group. The invention also provides novel intermediates useful for the preparation of Melphalan.

Abstract: Disclosed are powder solid compositions including a hydroalcoholic extract of Bergamot fruit (Citrus aurantium var. bergamia) and at least one phospholipid. Also disclosed is a process for the preparation of the compositions. The compositions are useful for the prevention and/or treatment of dysmetabolic syndromes, dyslipidemias and type 2 diabetes.

Abstract: The invention relates to a process for the preparation of colchicine 1 from colchicoside 2 which comprises enzymatic conversion of colchicoside 2 to 3-O-demethylcolchicine 3, wherein the enzyme used is a cellulase. According to another aspect of the invention, 3-O-demethylcolchicine 3 can be converted to colchicine 1 using an alkylating agent. The invention also relates to a process or enriching the colchicine 1 content of extracts from plants belonging to the Colchicaceae family containing colchicine 1, colchicoside 2 and 3-(9-demethyl colchicine 3, which comprises conversion by means of a colchicoside 2 cellulase to 3-O-demethylcolchicine 3, followed by conversion of 3-O-demethylcolchicine 3 to colchicine 1 using an alkylating agent.

Abstract: Disclosed is a process for the purification of staurosporine (1), which comprises salification of staurosporine (1) (Formula (1)) by treatment with a mineral acid to give a precipitated salt, isolation of the staurosporine (1) precipitated salt, treatment of the staurosporine (1) isolated salt with an organic base, and isolation of staurosporine (1). Also disclosed are novel polymorphic forms of the mono- and bis-hydrochloride salts of staurosporine (1).